Favorable outcomes for patients with refractory systemic lupus erythematosus treated with rituximab as evidenced with a follow-up of ≥ 10 years: a real-world evidence study
Rheumatology International · 28.04.2025 · 45 (5)
DOI: 10.1007/s00296-025-05879-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift Rheumatology International, online erschienen am 28.04.2025. Verfasst von Chrysanthi Staveri und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology, 1st Floor, Patras University Hospital, 26504, Rion, Patras, Greece. Hauptthemen laut MEDLINE: Lupus Erythematosus, Systemic, Rituximab, Immunologic Factors. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Patras.
Abstract (Originalsprache)
Treatment of Systemic Lupus Erythematosus (SLE) remains challenging. The aim of this real-world evidence study of patients with refractory SLE treated with rituximab (RTX) was to explore for any potential long-term effect(s) of this particular B cell depletion approach. This study included patients with SLE who had i) received at least 1 cycle of RTX and had ii) an at least 10 yr of follow-up after their first RTX infusion. Outcomes were assessed at 1 year and at their latest evaluation that was ≥ 10 yr after RTX treatment initiation. In cases where the SLE Disease Activity Index 2000 (cSLEDAI-2 k) was employed, a response was defined as a cSLEDAI-2 k of less than 4 in cases where the cSLEDAI-2 k was ≥ 4. In cases where the cSLEDAI-2 k was 2–4 at baseline, a response was defined as a cSLEDAI-2 k of 0. RTX was administered in 62 patients with SLE. For this real-world evidence study 23 patients (25 cases) with SLE (all Caucasian female, age range: 14–72 yr, mean: 31 yr) with active or relapsing disease, fulfilling inclusion criteria were enrolled. RTX treatment was associated with a response rate of 68.75% after 1 yr and 75% after ≥ 10 yr. The median cSLEDAI-2 K score decreased from 5.83 ± 3.70 at baseline to 1.95 ± 2.40 ( p < 0.001) at 1 yr and to 2.37 ± 3.00 ( p < 0.001) at the ≥ 10 yr time-point of follow-up. Our data suggest that RTX may indeed represent an alternative therapeutic option in patients with SLE refractory to standard treatment with an acceptable safety profile.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Rheumatology, 1st Floor, Patras University Hospital, 26504, Rion, Patras, Greece.
- Division of Rheumatology, "Agios Andreas" General Hospital, Patras, Greece.
- Division of Rheumatology, 1st Floor, Patras University Hospital, 26504, Rion, Patras, Greece. snliossis@med.upatras.gr.
- Division of Rheumatology, Department of Internal Medicine, University of Patras School of Medicine, Patras, Greece. snliossis@med.upatras.gr.
ORCID-Profile: Chrysanthi Staveri
Förderung
- University of Patras
Zitieren
APA
Staveri, C., Lykoura, C., Melissaropoulos, K., & Liossis, S. C. (2025). Favorable outcomes for patients with refractory systemic lupus erythematosus treated with rituximab as evidenced with a follow-up of ≥ 10 years: a real-world evidence study. Rheumatology International, 45(5). https://doi.org/10.1007/s00296-025-05879-3
Vancouver
Staveri C, Lykoura C, Melissaropoulos K, Liossis SC. Favorable outcomes for patients with refractory systemic lupus erythematosus treated with rituximab as evidenced with a follow-up of ≥ 10 years: a real-world evidence study. Rheumatology International. 2025;45(5). doi:10.1007/s00296-025-05879-3
BibTeX
@article{Staveri2025,
author = {Staveri, Chrysanthi and Lykoura, Chrysa and Melissaropoulos, Konstantinos and Liossis, Stamatis-Nick C},
title = {Favorable outcomes for patients with refractory systemic lupus erythematosus treated with rituximab as evidenced with a follow-up of ≥ 10 years: a real-world evidence study},
journal = {Rheumatology International},
year = {2025},
volume = {45},
number = {5},
doi = {10.1007/s00296-025-05879-3}
}
EUVIMED